yttrium radioisotopes has been researched along with Wet Macular Degeneration in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barak, A; Bennett, M; Dugel, PU; Jackson, TL; Nau, J; Petrarca, R; Weinberger, D | 2 |
| Barak, A; Bebchuk, JD; Binder, S; Dugel, PU; Jackson, TL; Nau, J; Reichel, E; Singer, M | 1 |
| Dugel, PU; Jackson, TL; Jaffe, GJ; Nau, J; Petrarca, R; Slakter, JS | 1 |
4 trial(s) available for yttrium radioisotopes and Wet Macular Degeneration
| Article | Year |
|---|---|
Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): month 24 safety and efficacy results.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Brachytherapy; Chronic Disease; Epiretinal Membrane; Female; Fluorescein Angiography; Humans; Intravitreal Injections; Male; Middle Aged; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Adjuvant; Ranibizumab; Strontium Radioisotopes; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration; Yttrium Radioisotopes | 2014 |
Macular epiretinal brachytherapy in treated age-related macular degeneration: MERITAGE study: twelve-month safety and efficacy results.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Brachytherapy; Chronic Disease; Female; Fluorescein Angiography; Humans; Intravitreal Injections; Male; Middle Aged; Prospective Studies; Radiotherapy Dosage; Ranibizumab; Retina; Strontium Radioisotopes; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity; Vitrectomy; Wet Macular Degeneration; Yttrium Radioisotopes | 2012 |
Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET).
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Brachytherapy; Female; Fluorescein Angiography; Follow-Up Studies; Humans; Intravitreal Injections; Macula Lutea; Male; Middle Aged; Radiotherapy Dosage; Ranibizumab; Strontium Radioisotopes; Treatment Outcome; Visual Acuity; Wet Macular Degeneration; Yttrium Radioisotopes | 2013 |
Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): month 12 optical coherence tomography and fluorescein angiography.
Topics: Brachytherapy; Epiretinal Membrane; Fluorescein Angiography; Humans; Macula Lutea; Prospective Studies; Radiotherapy Dosage; Strontium Radioisotopes; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity; Vitrectomy; Wet Macular Degeneration; Yttrium Radioisotopes | 2013 |